Thank you for sharing this comprehensive evaluation of your clinical case. The
diagnostic formulation of Generalized Anxiety Disorder (GAD), Major Depressive Disorder
(MDD), and Separation Anxiety Disorder appears well supported by the patient’s history and
symptom presentation. Your differentiation from Adjustment Disorder is accurate, as her
symptoms have persisted well beyond the six-month threshold defined by the DSM-5-TR
(American Psychiatric Association, 2022).
The pharmacologic plan to initiate escitalopram (Lexapro) 10 mg daily is evidence-based
and appropriate for treating both GAD and MDD. Recent research continues to support SSRIs,
particularly escitalopram, as first-line agents for these conditions due to their efficacy,
tolerability, and safety profile (Bandelow et al., 2022). Educating the patient on the delayed onset
of antidepressant benefits and the importance of adherence, as you described, aligns with best
practice and enhances therapeutic engagement.
The addition of propranolol 10 mg as needed for situational anxiety (such as pre-travel
anxiety) is also a rational adjunct. While beta-blockers are not first-line for chronic anxiety, they
are supported for performance- or event-related anxiety (Stahl, 2024). A recent systematic
review suggests propranolol remains a useful option for autonomic symptom control when used
in combination with psychotherapy and/or SSRIs (Cloos & Ferreira, 2021).
Your case also demonstrates excellent attention to psychosocial stressors and protective
factors, which are vital in anxiety management. Continued engagement in cognitive-behavioral
therapy (CBT) is strongly supported in recent literature as an effective combined approach with
SSRIs for GAD and comorbid depressive symptoms (Hofmann et al., 2020).
Given her trauma history and parenting stress, integrating trauma-informed CBT or
mindfulness-based interventions could further improve outcomes. Ensuring close follow-up
